Notice of Results

RNS Number : 5371J

Renalytix AI PLC

20 August 2019

 

Renalytix AI plc

("RenalytixAI" or the "Company")

Notice of results

Investor briefing

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical in vitro diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

Analyst briefing

An analyst briefing will take place at 1pm on Tuesday, 3 September 2019. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [e-mail] 

Investor briefing

A briefing open to all investors will take place on Tuesday, 3 September 2019 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [e-mail]

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)		Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)			Tel: [phone]
Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

 

END

 

 

NORSFWFLUFUSEIA